OpGen Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OpGen stock.
View analyst ratings for OpGen or view top-rated stocks.

Wall Street analysts have given OpGen a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but OpGen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

OpGen saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 873,400 shares, an increase of 47.7% from the February 28th total of 591,400 shares. Based on an average trading volume of 11,240,000 shares, the short-interest ratio is currently 0.1 days.
View OpGen's Short Interest.

OpGen is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for OpGen.

OpGen, Inc. (NASDAQ:OPGN) posted its quarterly earnings data on Wednesday, March, 24th. The medical research company reported ($0.37) EPS for the quarter, missing the Zacks' consensus estimate of ($0.31) by $0.06. The medical research company had revenue of $1.35 million for the quarter, compared to analysts' expectations of $1.30 million. OpGen had a negative net margin of 586.99% and a negative trailing twelve-month return on equity of 154.05%.
View OpGen's earnings history.

OpGen's stock was trading at $2.07 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, OPGN shares have increased by 12.1% and is now trading at $2.32.
View which stocks have been most impacted by COVID-19.

Shares of OpGen reverse split on the morning of Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 18th 2018. An investor that had 100 shares of OpGen stock prior to the reverse split would have 4 shares after the split.

2 equities research analysts have issued 1-year price objectives for OpGen's shares. Their forecasts range from $4.00 to $7.00. On average, they anticipate OpGen's stock price to reach $5.50 in the next twelve months. This suggests a possible upside of 137.1% from the stock's current price.
View analysts' price targets for OpGen or view top-rated stocks among Wall Street analysts.

Some companies that are related to OpGen include Celcuity (CELC), Centogene (CNTG), Exagen (XGN), Progenity (PROG), Enzo Biochem (ENZ), AnPac Bio-Medical Science (ANPC), Biocept (BIOC), Miragen Therapeutics (MGEN), Psychemedics (PMD), CannLabs (CANL), Cancer Genetics (CGIX), American Shared Hospital Services (AMS), American Shared Hospital Services (AMS), Avant Diagnostics (AVDX) and PotNetwork (POTN).
View all of OPGN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other OpGen investors own include Anavex Life Sciences (AVXL), Sorrento Therapeutics (SRNE), Energy Transfer (ET), Vaxart (VXRT), VBI Vaccines (VBIV), Nabriva Therapeutics (NBRV), SCYNEXIS (SCYX), Agile Therapeutics (AGRX), Pfizer (PFE) and Inovio Pharmaceuticals (INO).

(OPGN) raised $17 million in an initial public offering on Tuesday, May 5th 2015. The company issued 2,900,000 shares at a price of $5.50-$6.50 per share. Maxim Group acted as the underwriter for the IPO and National Securities was co-manager.

OpGen trades on the NASDAQ under the ticker symbol "OPGN."

Shares of OPGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OPGN stock can currently be purchased for approximately $2.32.

OpGen has a market capitalization of $88.78 million and generates $3.50 million in revenue each year. The medical research company earns $-12,450,000.00 in net income (profit) each year or ($6.90) on an earnings per share basis.

OpGen employs 38 workers across the globe.

The official website for OpGen is www.opgen.com.

OpGen is headquartered at 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878.

OpGen's mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The medical research company can be reached via phone at (301) 869-9683 or via email at [email protected]